Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Congenital isolated hyperinsulinism
Congenital isolated hyperinsulinism
Congenital isolated hyperinsulinism
Synonyms: PHHI, Persistent hyperinsulinemic hypoglycemia of infancy
Synonyms: PHHI, Persistent hyperinsulinemic hypoglycemia of infancy
Synonyms: PHHI, Persistent hyperinsulinemic hypoglycemia of infancy
Drug discovery
19
drugs
With orphan designations
Rare endocrine diseases
Congenital isolated hyperinsulinism
Overview
Congenital isolated hyperinsulinism (CHI) is a rare genetic disorder causing persistent hypoglycemia due to dysregulated insulin secretion from pancreatic β-cells. It is the most common cause of severe, recurrent hypoglycemia in neonates and infants, with up to 50% risk of permanent neurocognitive impairment if untreated. Genetic mutations (e.g., ABCC8, KCNJ11) disrupt insulin regulation, leading to excessive secretion independent of blood glucose levels [1][4][7].
Burden
Up to 25–50% risk of brain injury without prompt treatment [4][9].
High morbidity: Long-term neurodevelopmental delays, diabetes post-pancreatectomy, and pancreatic exocrine dysfunction in surgically treated cases [9][16].
Resource-intensive care: Requires frequent glucose monitoring, specialized centers, and multidisciplinary management [1][7].
Therapies
First-line: Diazoxide (KATP channel agonist) for diazoxide-responsive cases [4][16].
Second-line: Somatostatin analogs (octreotide, lanreotide) or glucagon for unresponsive cases; surgery (focal lesionectomy or subtotal pancreatectomy) for focal/diffuse forms [3][8][16].
Emergency: IV dextrose and glucagon to stabilize acute hypoglycemia [3][6].
Categories: rare endocrine diseases, rare genetic diseases, rare inborn errors of metabolism
Research Papers
712 drug discovery papers about Congenital isolated hyperinsulinism, with 1 first-in-class and 20 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
712 drug discovery papers about Congenital isolated hyperinsulinism, with 1 first-in-class and 20 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
proteins
2026-09-11 | Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.
Mutations in ABCC8 and KCNJ11 are associated with the most severe and diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are commonly used off-label as second-line treatment. While octreotide and lanreotide are the most established options, pasireotide-a second-generation somatostatin analogue with higher affinity for somatostatin receptor subtype 5-has been hypothesized to offer improved suppression of insulin secretion. We report the off-label use of subcutaneous pasireotide in an infant with severe CHI due to a homozygous ABCC8 mutation. The patient presented with severe persistent hypoglycemia despite high-dose octreotide, continuous glucagon infusion, and high carbohydrate requirement. The established next step would have been a subtotal pancreatectomy. Following detailed counseling, the parents expressed a strong preference to defer surgical intervention and to pursue further medical options. Thus, an individualized therapeutic trial with subcutaneous pasireotide was initiated at approximately 8 weeks of age as an attempt to avoid surgery. However, pasireotide at doses of up to 0.11 mg/kg/day administered every 4 h did not lead to substantial clinical improvement. Instead, treatment was associated with increased glycemic variability, as reflected by more frequent episodes of hypo- and hyperglycemia, ultimately requiring reintroduction of glucagon as rescue therapy. No adverse effects were observed. Due to the lack of therapeutic response, pasireotide was discontinued after 8 days and the patient underwent near-total pancreatectomy. In conclusion, intermittent pasireotide injections were not associated with clinical improvement in this infant with medically refractory CHI, and its use potentially contributed to increased glycemic variability and instability. Further studies are needed to evaluate the safety and efficacy of pasireotide in this vulnerable patient population.
2026-08-20 | Long-Term Results of Long-Acting Somatostatin Analog Therapy in Children with Congenital Hyperinsulinism.
Congenital hyperinsulinism (CHI) is a rare condition caused by dysregulation of pancreatic insulin secretion, leading to severe hypoglycemia in children. In diazoxide-unresponsive patients, somatostatin analogs are recommended as a treatment option. The aim of the present study was to evaluate the clinical characteristics, growth patterns, side effect profiles, and long-term follow-up of CHI patients who received octreotide long-acting release (octreotide-LAR) therapy. In the study, data from 23 CHI patients (F/M: 9/14) who received octreotide-LAR therapy between 2010 and 2025 were collected retrospectively. Data regarding glycemic control, growth parameters, and treatment-related adverse events were collected. The initial dose of octreotide-LAR was calculated as the total monthly dose of short-acting octreotide and was thereafter adjusted based on blood glucose monitoring results. The median age at diagnosis was 15 days (2-120), and the most common presenting symptom was hypoglycemic seizures (78.2%). Genetic mutations were identified in 14 patients (60.8%). Octreotide-LAR therapy was initiated at a median age of 14 (25th-75th quartiles: 9-24) months, and the mean treatment duration was 71.6±38.2 months (min-max: 7-162). Initial dose was calculated as total monthly dose of short acting octreotide which was adjusted per blood glucose monitoring results. Mean growth velocity during treatment was 6.4±1.1 cm/year with no concern of negative growth outcome. Neurodevelopmental delay was observed in 10 patients (43.4%). Apart from gallstones in three patients and mild, transiently elevated liver enzyme levels in six patients, no serious treatment-related side effects were observed. In our cohort, long-term octreotide-LAR therapy achieved normoglycemia in the majority of patients without negativegrowth outcome. Transient elevations in liver enzymes and cholelithiasis were the most frequently observed side effects, indicating a safety profile comparable to that of short-acting octreotide. These results suggested that octreotide-LAR therapy is an effective and safe treatment option for diazoxide-unresponsive patients with CHI.
2026-05-13 | Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.
Somatostatin is a potent endocrine regulator and neurotransmitter, exerting predominantly inhibitory effects in different tissues of the body, via G-protein coupled receptors. Five such specific receptors have been identified, with different effects and tissue distribution. The multifaceted actions and effects of somatostatin make it useful as a potential therapeutical means in various pathologies; however, in clinical practice, somatostatin analogues, namely octreotide, lanreotide and pasireotide, are commonly used instead, due to their increased half-life and increased receptor selectivity, with pasireotide showing a more extensive receptor binding profile and high affinity for somatotastin receptor (SSTR) 5, which may prove effective in cases of resistance to first-generation analogues. Apart from their many uses in neoplastic pathologies, somatostatin analogues represent viable treatment choices in some ocular pathologies, congenital hyperinsulinism, gastrointestinal bleedings and portal hypertension, acute pancreatitis, and dumping syndrome. They have also been used in some cases, with varying degrees of success, in patients with post-surgical gastrointestinal and lymphatic fistulas, refractory chronic diarrhoea and polycystic kidney disease; many applications in paediatric patients have also been documented. The aim of this review is to present the applications of somatostatin and its analogues as alternative or second-line therapies, along with insights into their effectiveness and future potential.
2025-11-07 | Advances in Pharmacotherapy for Congenital Hyperinsulinism.
Congenital hyperinsulinism (CHI) is a rare disorder causing persistent hypoglycaemia in infants due to excessive insulin secretion from pancreatic β-cells. It has genetic causes, primarily mutations in ATP-sensitive potassium channel genes (ABCC8, KCNJ11). CHI manifests in three forms-focal, diffuse, and atypical-distinguished by histology and genetics, influencing treatment strategies. Early diagnosis and tailored management are vital to prevent neurological damage. While transient CHI resolves spontaneously, permanent CHI often requires complex medical and/or surgical intervention. Despite advances, long-term neurodisability remains high, highlighting increased need to improve monitoring as well as better therapies with lesser side effects. Acute treatment aims to rapidly normalize glucose levels and long-term treatments include diazoxide (KATP channel agonist) to suppress insulin secretion, though its effectiveness depends on genetic mutation type. Other therapies include somatostatin analogues. Newer emerging therapies include novel glucagon analogues, monoclonal antibodies targeting insulin receptors, GLP-1 receptor antagonist, and selective somatostatin receptor agonist, currently under clinical trials. Along with medical treatment, children may require additional feeding support with carbohydrate supplementation using glucose polymers and special formulas. Continuous glucose monitoring aids detection but has limitations. Surgery is preferred for focal lesions to potentially cure CHI.
2025-10-13 | Treatment of Congenital Hyperinsulinism With a Novel, Long-acting Glucagon Analogue.
Congenital hyperinsulinism (HI) is a disorder of insulin regulation that results in hypoketotic hypoglycemia and is associated with a high risk of neurological sequalae from hypoglycemia-induced brain damage. There is only 1 Food and Drug Administration-approved drug for the treatment of HI, and up to 60% of patients do not respond to it; thus, there is a significant unmet need for new treatments. We report a case of a 29-year-old female with HI due to an activating glucokinase pathogenic variant, who was diagnosed as an adult and continued to have persistent hypoglycemia despite standard-of-care therapy. The patient was enrolled in the phase II clinical trial evaluating efpegerglucagon, a novel long-acting glucagon analog. She has continued treatment with efpegerglucagon through a single-patient Investigational New Drug Expanded Access Program and has demonstrated improved glycemic control throughout 10 months of treatment. Efpegerglucagon may be a viable treatment option or adjunct therapy for patients with HI who are unresponsive or partially responsive to currently available therapies.
small molecules
2026-09-24 | A Novel ABCC8 Variant in an Adult with Hyperinsulinemic Hypoglycemia Suggestive of Congenital Hyperinsulinism: A Case Report.
Background and Clinical Significance: Congenital hyperinsulinism (CHI) is a disorder involving excessive insulin secretion due to mutations in the insulin regulation pathways. Patients are typically diagnosed during infancy following recurrent hypoglycemic events, which may lead to irreversible neurologic damage if left untreated. Adult presentation and diagnosis are rare. Case Presentation: Here, we report the unusual case of a 41-year-old patient who presented with recurrent episodes of hyperinsulinemic hypoglycemia. An extensive diagnostic evaluation yielded no evidence of an acquired cause. Genetic testing revealed a heterozygous novel c.4078G>C substitution in the ABCC8 gene, which plays a role in the insulin secretion pathway. This variant may have been the cause for CHI going unrecognized during the patient's childhood and could have also contributed to his uncontrolled convulsive disorder. Treatment with diazoxide and octreotide led to significant clinical improvement, with no severe hypoglycemic events during the final week of hospitalization. Conclusions: This case emphasizes the importance of considering congenital hyperinsulinism in the differential diagnosis of adult patients evaluated for hyperinsulinemic hypoglycemia, especially when standard workup fails to identify an underlying cause.
2026-09-13 | Demand Breastfeeding in Infants using Diazoxide to manage Congenital Hyperinsulinism.
Congenital Hyperinsulinism (CHI) is a rare condition which causes severe and profound hypoglycaemia. Breastfeeding is often stopped at diagnosis of CHI to reduce the likelihood of fluid overload during treatment with diazoxide, but without supportive evidence. Breastfeeding confers numerous advantages to all newborn babies and their mothers and may be safe and effective in babies with CHI. We aimed to evaluate whether demand breastfeeding in babies and infants with CHI receiving diazoxide therapy maintains safe glycaemic stability without risk of fluid overload. A retrospective observational review was undertaken to test safety, efficacy and acceptability of breastfeeding alongside diazoxide treatment in 17 infants with biochemically confirmed CHI. Data was collected on feeding method, glycaemic outcomes, adverse effects, signs/symptoms of fluid overload and genetic aetiology of CHI. The cohort included 17 infants (13 males, 4 females). Two patients had genetic forms of CHI; due to ABCC8 and HNF4A variants, while the remaining infants were diagnosed with transient CHI. All infants were demand breastfed; four infants transitioned from restricted bottle feeding to successful demand breastfeeding during the treatment course. Duration of diazoxide therapy ranged from 5-13 weeks in patients with transient CHI. The two patients with genetic CHI required prolonged therapy, with treatment durations of 9-18 months at the time of the study. Glycaemic stability was maintained throughout the treatment period without any increase in hypoglycaemic episodes during transfer to breastfeeding or reductions in diazoxide. There was no clinical evidence of fluid overload across the patient cohort. No diazoxide related adverse effects were observed, and therapy did not interfere with breastfeeding progression. Study findings support the feasibility and safety of demand breastfeeding in infants receiving diazoxide for CHI. This supports metabolic stability and parental feeding goals. These findings suggest that breastfeeding should not be routinely discouraged in this population and can be safely pursued with appropriate monitoring.
2026-08-19 | Glucagon in Endocrine and Metabolic Practice: A Critical Narrative Review of Stimulation Testing, Diagnostic Cut-points and Therapeutic Use in Children, Adolescents and Adults
Glucagon occupies an unusual position in clinical endocrinology. The same 29-amino-acid peptide serves as a provocative agent for pituitary function testing, as an emergency treatment for severe hypoglycaemia, as a continuous infusion in hyperinsulinaemic states of infancy, and, through receptor co-agonism, as a component of the newest generation of cardiometabolic drugs. These applications have developed in parallel, largely within separate literatures, and the assumptions that underpin them have rarely been examined together. This review evaluates the evidence accumulated over approximately a quarter of a century on the glucagon stimulation test and on therapeutic glucagon across the paediatric and adult lifespan, with particular attention to the derivation, transportability and validity of diagnostic cut-points. Evidence was identified through structured searching of biomedical and bibliographic sources and appraised for design adequacy, reference-standard quality, sample size, assay dependence and generalisability. Three findings dominate the synthesis. First, the growth hormone cut-point for the glucagon stimulation test is not a fixed biological threshold but a function of dose regimen, adiposity, glucose tolerance, age and assay calibration; the widely used threshold of 3 µg/L overdiagnoses deficiency in overweight adults, and the proposed alternative of 1 µg/L rests on small validation cohorts. Second, the corticotroph read-out from the same test performs considerably less well than the somatotroph read-out, and several independent series show a broad indeterminate zone in which the test cannot classify patients reliably. Third, therapeutic glucagon has been transformed by stable ready-to-use formulations and by the analogue dasiglucagon, with randomised evidence in severe hypoglycaemia, congenital hyperinsulinism and post-bariatric hypoglycaemia, although comparative effectiveness data and long-term paediatric safety data remain sparse. Priorities include multicentre cut-point validation stratified by body mass index and assay platform, harmonised cortisol thresholds, and adequately powered comparisons between glucagon formulations in real-world hypoglycaemia.
2026-08-06 | Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.
KATP-channel-related hyperinsulinism (KATPHI) is a rare genetic disorder of the pancreatic beta cells, manifesting as life-threatening hypoglycemia in neonates due to excessive insulin secretion. Management of the severe diffuse form of KATPHI currently lacks treatment options, as the first-line therapy octreotide is often insufficiently effective, necessitating radical pancreatectomy in many patients. In this study, we differentiated stem cells carrying the KATPHI-causing mutation KCNJ11-/- to stem cell-derived islets (SC-islets) to develop new pharmaceutical therapies for KATPHI. We tested seven candidate molecules in vitro and the most effective ones in vivo in immunocompromised mice that were transplanted with the human KCNJ11-/- SC-islets. KCNJ11 -/- SC-islets inappropriately secreted 3.9 times more insulin in low glucose than KCNJ11+/+ controls. Transplanted KCNJ11-/- SC-islets caused persistent hyperinsulinemia and hypoglycemia to the recipient mice. We tested acyl-ghrelin identified in our in vitro experiments and its long-acting analogue relamorelin in these mice. Acyl-ghrelin and relamorelin alone increased fasting blood glucose. Combining relamorelin with octreotide increased blood glucose synergistically, ie, more than the sum of each drug alone, reverting hypoglycemia to normoglycemia while reducing the excessive insulin secretion. We show that ghrelin-receptor agonists have acute anti-hypoglycemic effects in a humanized mouse model of KATPHI, especially when combined with octreotide. Relamorelin has been tested in >650 diabetic adults with little side effects, leading us to propose relamorelin-octreotide combination for further development as a therapeutic candidate for severe KATPHI patients.
2026-07-23 | Indocyanine green fluorescence cholangiography enables safe laparoscopic near-total pancreatectomy for diffuse congenital hyperinsulinism.
Laparoscopic near-total pancreatectomy (NTP) for diffuse congenital hyperinsulinism (CHI) may reduce morbidity compared with open surgery. However, it is technically limited by uncertainty regarding the intrapancreatic common bile duct (CBD) course, risking bile duct injury or inadequate resection. We evaluated whether near-infrared indocyanine green fluorescence cholangiography (NIR ICG FC) improves intraoperative identification of the intrapancreatic CBD and supports laparoscopic NTP for medically-refractory diffuse CHI. We performed a retrospective single-centre review of consecutive infants undergoing laparoscopic NTP with NIR ICG FC for diffuse CHI (2021-2025). Intravenous ICG (0.5 mg/kg) was administered 10-15 h preoperatively. Outcomes included feasibility of CBD visualisation, extent of resection, biliary complications, postoperative recovery, persistence of hyperinsulinism and medium-term endocrine/exocrine function. Five infants underwent laparoscopic NTP at a median age of 3 months (range 2-6). The intrapancreatic CBD was visualised in all cases, enabling a consistent 95% resection without conversion to open surgery. There were no bile duct injuries. Enteral feeding commenced at a median of 3 postoperative days (range 2-4). One patient developed transient obstructive jaundice on postoperative day 13 that resolved with conservative management. At a median follow-up of 30 months (range 20-51), three infants had residual hyperinsulinism (managed by feeding strategies in two and medication in one), and one had exocrine insufficiency requiring enzyme supplementation; no child had diabetes at latest follow up. NIR ICG fluorescence cholangiography provides real time delineation of the intrapancreatic CBD and can support a safe minimally invasive approach to near-total pancreatectomy for diffuse CHI.
gene therapies
2025-05-18 | Comprehensive clinical and molecular characterization with long-term outcomes in 40 patients with congenital hyperinsulinism.
Congenital hyperinsulinism (CHI) represents the most frequent cause of recurrent hypoglycemia in neonates and infants, stemming from defects in the regulatory pathways of insulin secretion from pancreatic beta cells. This study aims to assess the clinical and genetic characteristics of a CHI cohort and to discuss the complexities involved in managing this heterogeneous disorder. Forty patients (23 girls) with CHI were included in the study. Data on the diagnosis and treatment of CHI were obtained from the medical records. The median age at diagnosis was 1.4 months (range 0.1-30 months). The mean gestational age was 37.8 ± 2.4 weeks, and the birth weight was 1.1 ± 2.0 SDS. The consanguinity ratio was 35.0%. Median glucose, insulin, and C-peptide concentrations at diagnosis were 34.0 mg/dl (IQR 25.2-41.7), 12.4µU/ml (IQR 4.4-27.1), and 1.5 ng/ml (IQR 0.7-3.8), respectively. Molecular genetic diagnosis could be established in 62.5% (n = 25). Pathogenic variants were predominantly identified in the KATP channel genes (17/25, 68%), with the ABCC8 being the most frequent (n = 15; biallelic: 8, monoallelic: 7). KCNJ11 variants were identified in two (5.0%), GLUD1 variants in three (7.5%), and HADH variants in five patients (12.5%). Pancreatectomy was performed in 10 patients, with a mean age at the time of surgery of 3.9 ± 3.2 months. The genetic etiology was identified in all patients who underwent pancreatectomy, all of whom had defects in the KATP channel. ABCC8 variants were detected in nine (biallelic: 5, monoallelic: 4), while a biallelic variant in the KCNJ11 was identified in one case. A molecular genetic diagnosis was identified in approximately two-thirds of our cohort, underscoring the significance of genetic testing in the management of CHI. Ongoing advances in genetic technologies are anticipated to enhance our understanding of the etiopathogenesis of CHI and support the development of more personalized therapeutic strategies. Although the genotype-phenotype correlation remains only partially elucidated, specific genetic variants may provide predictive insights into treatment resistance, thereby informing more targeted treatment approaches.
2025-04-11 | The genetics of low and high birthweight and their relationship with cardiometabolic disease.
Low birthweight infants are at increased risk not only of mortality, but also of type 2 diabetes mellitus and CVD in later life. At the opposite end of the spectrum, high birthweight infants have increased risk of birth complications, such as shoulder dystocia, neonatal hypoglycaemia and obesity, and similarly increased risk of type 2 diabetes mellitus and CVD. However, previous genome-wide association studies (GWAS) of birthweight in the UK Biobank have primarily focused on individuals within the 'normal' range and have excluded individuals with high and low birthweight (<2.5 kg or >4.5 kg). The aim of this study was to investigate genetic variation associated within the tail ends of the birthweight distribution, to: (1) see whether the genetic factors operating in these regions were different from those that explained variation in birthweight within the normal range; (2) explore the genetic correlation between extremes of birthweight and cardiometabolic disease; and (3) investigate whether analysing the full distribution of birthweight values, including the extremes, improved the ability to detect genuine loci in GWAS. We performed case-control GWAS analysis of low (<2.5 kg) and high (>4.5 kg) birthweight in the UK Biobank using REGENIE software (Nlow=20,947; Nhigh=12,715; Ncontrols=207,506) and conducted three continuous GWAS of birthweight, one including the full range of birthweights, one involving a truncated GWAS including only individuals with birthweights between 2.5 and 4.5 kg and a third GWAS that winsorised birthweight values <2.5 kg and >4.5 kg. Additionally, we performed bivariate linkage disequilibrium (LD) score regression to estimate the genetic correlation between low/normal/high birthweight and cardiometabolic traits. Bivariate LD score regression analyses suggested that high birthweight had a mostly similar genetic aetiology to birthweight within the normal range (genetic correlation coefficient [rG]=0.91, 95% CI 0.83, 0.99), whereas there was more evidence for a separate set of genes underlying low birthweight (rG=-0.74, 95% CI 0.66, 0.82). Low birthweight was also significantly positively genetically correlated with most cardiometabolic traits and diseases we examined, whereas high birthweight was mostly positively genetically correlated with adiposity and anthropometric-related traits. The winsorisation strategy performed best in terms of locus detection, with the number of independent genome-wide significant associations (p<5×10-8) increasing from 120 genetic variants at 94 loci in the truncated GWAS to 270 genetic variants at 178 loci, including 27 variants at 25 loci that had not been identified in previous birthweight GWAS. This included a novel low-frequency missense variant in the ABCC8 gene, a gene known to be involved in congenital hyperinsulinism, neonatal diabetes mellitus and MODY, that was estimated to be responsible for a 170 g increase in birthweight amongst carriers. Our results underscore the importance of genetic factors in the genesis of the phenotypic correlation between birthweight and cardiometabolic traits and diseases.
2024-12-25 | Case report: Duplication of the GCK gene is a novel cause of nesidioblastosis: evidence from a case with Silver-Russell syndrome-like phenotype related to chromosome 7.
Silver-Russell syndrome (SRS) is a syndrome characterized by prenatal and postnatal growth retardation, facial features, and body asymmetry. SRS is often complicated with hypoglycemia, whose etiology is unclear. We describe the clinical course of 25-year-old man with hypoglycemia. We diagnosed him with hyperinsulinemic hypoglycemia (HH) and treated him with laparoscopic distal pancreatectomy. Histological examination led to a diagnosis of nesidioblastosis. The juvenile onset of his nesidioblastosis and its slowly progressive course suggested a genetic etiology. Whole-exome sequencing (WES) identified the heterozygous NR0B2 Ala195Ser variant, which alone was unlikely to cause nesidioblastosis because this variant is sometimes detected in the Japanese population. Copy number analysis using WES data suggested duplication in chromosome 7, and subsequent G-banding chromosome analysis confirmed mos dup(7)(p11.2p14). We determined that the patient had SRS-like phenotype based on his clinical features and this duplication. Furthermore, we found that the duplicated region contained the GCK gene, whose gain-of function variants could cause HH. Taken together, the patient's HH may have been caused by duplication of the GCK gene, which could be a novel cause of nesidioblastosis.
2023-07-20 | A novel mutation in the KCNJ11 gene (p.Val36Glu), predisposes to congenital hyperinsulinemia.
The hypoglycemia induced by insulin hypersecretion in congenital hyperinsulinemia (CHI), a rare life-threatening condition can lead to irreversible brain damage in neonates. Inactivating mutations in the genes encoding KATP channel (ABCC8 and KCNJ11) as well as HNF4A, HNF1A, HADH, UCP2, and activating mutations in GLUD1, GCK, and SLC16A1 have been identified as causal. A 3-month-old male infant presenting tonic-clonic seizures and hyperinsulinemia was clinically assessed and subjected to genetic analysis. Besides the index patient, his parents were clinically investigated, and a detailed family history was also recorded. The laboratory investigations and the genetic test results of the parents were compared with the index patient. The biochemical and hormonal profile of the patient confirmed his suffering from CHI and did not respond to diazoxide treatment. The genetic testing revealed that the subject harbored a novel homozygous missense mutation in the KCNJ11 gene, (c.107T>A, p.Val36Glu.). The bioinformatic analysis revealed that valine is highly conserved and predicted that the variant allele (p.Val36Glu) is likely pathogenic and causal for CHI. Parents were heterozygous carriers and did not report any abnormal metabolic profile. Identification of such mutations is critical and likely to change the therapeutic interventions for such patients in the future.
2022-11-08 | Integration of genomic analysis and transcript expression of ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism.
The focal form of CHI is caused by an autosomal recessive pathogenic variant affecting the paternal homologue of genes ABCC8 or KCNJ11 and a second somatic event specifically occurring in the affected islet of Langerhans. The approach of this study was to integrate the genetic changes occurring in pancreatic focal lesions of CHI at the genomic and transcriptional level. Patients receiving therapeutic surgery and with proven ABCC8 or KCNJ11 pathogenic variants were selected and analyzed for loss of heterozygosity (LOH), changes in copy number and uniparental disomy (UPD) on the short am of chromosome 11 by molecular microarray analysis and methylation-specific MLPA. Gene expression was analyzed by RT-PCR and Massive Analysis of cDNA Ends (MACE). Both genes, ABCC8 and KCNJ11, are located in proximity to the Beckwith-Wiedemann (BWS) imprinting control region on chromosome 11p15. Somatic paternal uniparental isodisomy (UPD) at chromosome 11p was identified as second genetic event in focal lesions resulting in LOH and monoallelic expression of the mutated ABCC8/KCNJ11 alleles. Of five patients with samples available for microarray analysis, the breakpoints of UPD on chromosome 11p were different. Samples of two patients were analyzed further for changes in gene expression. Profound downregulation of growth suppressing genes CDKN1 and H19 was detected in focal lesions whereas growth promoting gene ASCL2 and pancreatic transcription factors of the endocrine cell lineage were upregulated. Paternal UPD on the short arm of chromosome 11 appears to be the major second genetic event specifically within focal lesions of CHI but no common breakpoint for UDP can be delineated. We show for the first time upregulation of growth promoting ASCL2 (achaete-scute homolog 2) suggestive of a driving factor in postnatal focal expansion in addition to downregulation of growth suppressing genes CDKN1C and H19.
cell therapies
2026-09-28 | Congenital Hyperinsulinism With Paternally Inherited ABCC8 Variants: A Single Center Experience Over a Decade in Singapore.
ABCC8 pathogenic variants have been found to cause neonatal diabetes mellitus (NDM), maturity-onset diabetes of the young (MODY) and congenital hyperinsulinism (CHI), depending on the nature of the mutation. Few studies have reported on the carrier frequency of CHI-related ABCC8 variants. In Singapore, the carrier rate is 1 in 754. Paternally inherited ABCC8 recessive variants have been classically associated with focal lesions causing CHI. In our case series of five patients with paternally inherited ABCC8 variants, one patient had a second maternally inherited recessive variant, making him a compound heterozygous genotype presenting with severe, neonatal onset, diffuse disease that was not responsive to diazoxide. The remaining four patients had a single paternally inherited ABCC8 variant, of which three were previously reported to be recessive variants-only 1 had a focal lesion while the rest had diffuse disease. A comprehensive review of our cases suggests that patients with paternally inherited ABCC8 variants, whether autosomal recessive, heterozygous, or associated with genetic syndromes, were heterogeneous in their clinical manifestations and cannot be reliably distinguished based on their initial clinical presentation. A deeper understanding of the genotype-phenotype correlation of ABCC8-related CHI will require further research and functional analyses. Both a genetic diagnosis and imaging using 18F-DOPA-PET should be pursued in a timely manner once diazoxide unresponsiveness has been established. Single-stage near-total pancreatectomy may be considered for patients with diffuse disease.
2026-09-27 | Laparoscopic Pancreatectomy for Persistent Hyperinsulinemic Hypoglycemia of Infancy - Case Series.
Hypoglycemia in neonates can be attributed to Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI). Even though initial management involves the use of medical agents, requirement of surgery is seen in a large number of cases, particularly in those who are nonresponsive. Open pancreatectomy has been the gold standard in the management of PHHI, but there has been a recent inclination toward the use of minimally invasive procedures, namely laparoscopic pancreatectomy to achieve similar results with lesser morbidity. The aim of this study is to describe the presentation, key technical points, and outcomes of laparoscopic pancreatectomy in the management of PHHI. A retrospective study which was conducted between January 2019 and September 2024 which included 7 children who were diagnosed to have PHHI. All seven patients who were operated were infants with an average age of 4 months (range 1-5 months), with the youngest patient being one and half months of age. All of them underwent a laparoscopic pancreatectomy with the average duration of the procedure being 60 min and with very minimal blood loss. A distal pancreatectomy was performed in one infant while a near total pancreatectomy was performed in the other six infants. Euglycemia was achieved in six cases and they are on regular follow-up, with the longest duration of follow-up being 4 years and 3 months. The average duration of follow-up has been 3 years and 6 months, ranging from 1 month to 4 years and 3 months. One child had postoperative requirement of octreotide for 2 weeks after which it was tapered and stopped. One child had persistent hypoglycemic episodes and required a completion pancreatectomy 6 months after the initial surgery. No intraoperative or postoperative complications were noted. Laparoscopic pancreatectomy is an excellent tool in the armamentarium of surgeons looking for an effective surgical modality to treat PHHI with minimal morbidity.
2026-09-13 | Minimally Invasive Surgical Treatment of Different Types of Hyperinsulinism.
Congenital hyperinsulinism of infancy (CHI) is a rare and genetically heterogeneous disorder that often requires surgical intervention when medical therapy fails. Distinct pathological subtypes of CHI necessitate different surgical strategies. Minimally invasive surgery has increasingly been considered a safe and feasible approach for these patients. This study aimed to evaluate the outcomes of minimally invasive surgery for different CHI subtypes at our center. We conducted a retrospective single-center review of 110 patients with CHI who underwent minimally invasive surgery between 2011 and 2024. Pathological subtypes comprised 45 focal, 64 diffuse, and one atypical case. 18F-DOPA PET/CT was performed in 97 patients, demonstrating a diagnostic concordance rate of 94.8%. Conversion to open surgery was required in three patients (two focal and one diffuse) because of intraoperative bleeding, whereas the remaining 107 procedures were completed minimally invasively, including eight robotic-assisted operations (five focal and three diffuse). Among patients with focal CHI, 91.1% achieved cure without postoperative medication. In diffuse disease, near-total pancreatectomy resulted in a higher cure rate than subtotal resection (66.7% vs. 51.2%) but was associated with an increased incidence of postoperative hyperglycemia and common bile duct injury. Two patients required reoperation because of persistent hypoglycemia. Minimally invasive surgery is a safe and feasible treatment for CHI, providing outcomes comparable to open surgery. Focal CHI is associated with excellent postoperative outcomes and may benefit from earlier surgical intervention. For diffuse CHI, approximately 95% pancreatectomy may achieve satisfactory glycemic control while balancing the risk of postoperative complications.
2026-01-31 | Robotic versus Open Pancreatectomy for Focal Congenital Hyperinsulinism in Infants: A Single-Center Study.
Focal forms of congenital hyperinsulinism (FoCHI) are rare pediatric conditions managed using established metabolic and surgical protocols. To date, the use of a robotic approach for this surgery in children has not been described. We present our initial experience with robotic pancreatectomy, compared with the open approach, for the management of FoCHI. We conducted a retrospective, single-center study involving 25 children who underwent pancreatectomy for CHI between 2011 and 2024. Collected data included patient demographics, surgical details, complications, and post-operative outcomes. The Da Vinci Xi robotic system was used for all robotic procedures. Ten patients underwent robotic pancreatectomy, and 10 underwent open surgery; five children treated laparoscopically were excluded. There were no significant differences between the robotic and open groups in median weight at surgery (7.7 kg vs. 7.3 kg, p = 0.7), median age (7 months vs. 5.9 months, p = 0.48), median operative time (298 minutes vs. 285 minutes, p = 0.5), length of stay (14 days vs. 14.5 days, p = 0.26), or time to postoperative feeding resumption (4 days vs. 4.5 days, p = 0.68). Intraoperatively, 80% of lesions were visible on the pancreatic surface. Two cases of incomplete resection occurred in each group; after multidisciplinary review, both patients in the robotic group required a second procedure. No intraoperative bleeding or conversions were reported. The overall cure rate was 90% in the robotic group and 80% in the open surgery group. This preliminary study suggests that robotic pancreatectomy for congenital hyperinsulinism may be both safe and feasible. The robotic approach provides enhanced visualization of small vessels, enabling limited dissection and safe resection. Given the sample size, further studies are required to confirm these findings.
2025-09-23 | A rare case of congenital hyperinsulinism in a child — when morphology determines treatment tactics
Background. A clinical case of an encapsulated focal form of congenital hyperinsulinism in a young child is presented. A comprehensive examination was performed, including molecular genetic analysis, radionuclide diagnostics (PET-CT with 18F-DOPA) and intraoperative histological examination. During morphological analysis, an encapsulated focus of β-cell adenomatous hyperplasia was verified, located in the head of the pancreas. This finding necessitated an extended organ resection. It is particularly noteworthy that there is a clear fibrous capsule around the pathological focus, which presents a diagnostic challenge in differentiating this pathology from an insulinoma. The postoperative period was uneventful, and stable normoglycemia was achieved, which ultimately confirmed the positive outcome of the treatment and the patient's recovery. The unique feature of this clinical case is that it represents the first recorded example of the focal form of congenital hyperinsulinism, characterized by a well-defined fibrous capsule combined with adenomatosis lacking visible boundaries. As of today, similar observations have not been found in available publications from domestic medical centers, which highlights the rarity of the described case and its significance for expanding knowledge about the spectrum of focal forms of this disease. Analysis of this morphological variant highlights the importance of performing a rapid histological examination of tissues during surgery, which in this clinical case was a key factor in determining the extent of the resection. This decision allowed us not to be limited to just the encapsulated formation and ultimately led to the patient's full recovery. Conclusion. This case demonstrates the importance of a multidisciplinary approach in the diagnosis of rare forms of congenital hyperinsulinism and highlights the need for a thorough histopathological examination of the surgical material to achieve correct clinical decision.
other
2023-06-26 | Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
Congenital hyperinsulinism (HI) is a genetic disorder in which pancreatic β-cell insulin secretion is excessive and results in hypoglycemia that, without treatment, can cause brain damage or death. Most patients with loss-of-function mutations in ABCC8 and KCNJ11, the genes encoding the β-cell ATP-sensitive potassium channel (KATP), are unresponsive to diazoxide, the only U.S. Food and Drug Administration–approved medical therapy and require pancreatectomy. The glucagon-like peptide 1 receptor (GLP-1R) antagonist exendin-(9-39) is an effective therapeutic agent that inhibits insulin secretion in both HI and acquired hyperinsulinism. Previously, we identified a highly potent antagonist antibody, TB-001-003, which was derived from our synthetic antibody libraries that were designed to target G protein–coupled receptors. Here, we designed a combinatorial variant antibody library to optimize the activity of TB-001-003 against GLP-1R and performed phage display on cells overexpressing GLP-1R. One antagonist, TB-222-023, is more potent than exendin-(9-39), also known as avexitide. TB-222-023 effectively decreased insulin secretion in primary isolated pancreatic islets from a mouse model of hyperinsulinism, Sur1−/− mice, and in islets from an infant with HI, and increased plasma glucose levels and decreased the insulin to glucose ratio in Sur1−/− mice. These findings demonstrate that targeting GLP-1R with an antibody antagonist is an effective and innovative strategy for treatment of hyperinsulinism. Article Highlights Patients with the most common and severe form of diazoxide-unresponsive congenital hyperinsulinism (HI) require a pancreatectomy. Other second-line therapies are limited in their use because of severe side effects and short half-lives. Therefore, there is a critical need for better therapies. Studies with the glucagon-like peptide 1 receptor (GLP-1R) antagonist, avexitide (exendin-(9-39)), have demonstrated that GLP-1R antagonism is effective at lowering insulin secretion and increasing plasma glucose levels. We have optimized a GLP-1R antagonist antibody with more potent blocking of GLP-1R than avexitide. This antibody therapy is a potential novel and effective treatment for HI.
2022-11-01 | Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism
Gene expression is tightly regulated, with many genes exhibiting cell-specific silencing when their protein product would disrupt normal cellular function1. This silencing is largely controlled by non-coding elements, and their disruption might cause human disease2. We performed gene-agnostic screening of the non-coding regions to discover new molecular causes of congenital hyperinsulinism. This identified 14 non-coding de novo variants affecting a 42-bp conserved region encompassed by a regulatory element in intron 2 of the hexokinase 1 gene (HK1). HK1 is widely expressed across all tissues except in the liver and pancreatic beta cells and is thus termed a ‘disallowed gene’ in these specific tissues. We demonstrated that the variants result in a loss of repression of HK1 in pancreatic beta cells, thereby causing insulin secretion and congenital hyperinsulinism. Using epigenomic data accessed from public repositories, we demonstrated that these variants reside within a regulatory region that we determine to be critical for cell-specific silencing. Importantly, this has revealed a disease mechanism for non-coding variants that cause inappropriate expression of a disallowed gene. De novo variants altering a conserved region in an intron of HK1 cause congenital hyperinsulinism by perturbing the activity of a putative cell type-specific regulatory element.
proteins
2026-09-11 | Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.
Mutations in ABCC8 and KCNJ11 are associated with the most severe and diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are commonly used off-label as second-line treatment. While octreotide and lanreotide are the most established options, pasireotide-a second-generation somatostatin analogue with higher affinity for somatostatin receptor subtype 5-has been hypothesized to offer improved suppression of insulin secretion. We report the off-label use of subcutaneous pasireotide in an infant with severe CHI due to a homozygous ABCC8 mutation. The patient presented with severe persistent hypoglycemia despite high-dose octreotide, continuous glucagon infusion, and high carbohydrate requirement. The established next step would have been a subtotal pancreatectomy. Following detailed counseling, the parents expressed a strong preference to defer surgical intervention and to pursue further medical options. Thus, an individualized therapeutic trial with subcutaneous pasireotide was initiated at approximately 8 weeks of age as an attempt to avoid surgery. However, pasireotide at doses of up to 0.11 mg/kg/day administered every 4 h did not lead to substantial clinical improvement. Instead, treatment was associated with increased glycemic variability, as reflected by more frequent episodes of hypo- and hyperglycemia, ultimately requiring reintroduction of glucagon as rescue therapy. No adverse effects were observed. Due to the lack of therapeutic response, pasireotide was discontinued after 8 days and the patient underwent near-total pancreatectomy. In conclusion, intermittent pasireotide injections were not associated with clinical improvement in this infant with medically refractory CHI, and its use potentially contributed to increased glycemic variability and instability. Further studies are needed to evaluate the safety and efficacy of pasireotide in this vulnerable patient population.
2026-08-20 | Long-Term Results of Long-Acting Somatostatin Analog Therapy in Children with Congenital Hyperinsulinism.
Congenital hyperinsulinism (CHI) is a rare condition caused by dysregulation of pancreatic insulin secretion, leading to severe hypoglycemia in children. In diazoxide-unresponsive patients, somatostatin analogs are recommended as a treatment option. The aim of the present study was to evaluate the clinical characteristics, growth patterns, side effect profiles, and long-term follow-up of CHI patients who received octreotide long-acting release (octreotide-LAR) therapy. In the study, data from 23 CHI patients (F/M: 9/14) who received octreotide-LAR therapy between 2010 and 2025 were collected retrospectively. Data regarding glycemic control, growth parameters, and treatment-related adverse events were collected. The initial dose of octreotide-LAR was calculated as the total monthly dose of short-acting octreotide and was thereafter adjusted based on blood glucose monitoring results. The median age at diagnosis was 15 days (2-120), and the most common presenting symptom was hypoglycemic seizures (78.2%). Genetic mutations were identified in 14 patients (60.8%). Octreotide-LAR therapy was initiated at a median age of 14 (25th-75th quartiles: 9-24) months, and the mean treatment duration was 71.6±38.2 months (min-max: 7-162). Initial dose was calculated as total monthly dose of short acting octreotide which was adjusted per blood glucose monitoring results. Mean growth velocity during treatment was 6.4±1.1 cm/year with no concern of negative growth outcome. Neurodevelopmental delay was observed in 10 patients (43.4%). Apart from gallstones in three patients and mild, transiently elevated liver enzyme levels in six patients, no serious treatment-related side effects were observed. In our cohort, long-term octreotide-LAR therapy achieved normoglycemia in the majority of patients without negativegrowth outcome. Transient elevations in liver enzymes and cholelithiasis were the most frequently observed side effects, indicating a safety profile comparable to that of short-acting octreotide. These results suggested that octreotide-LAR therapy is an effective and safe treatment option for diazoxide-unresponsive patients with CHI.
2026-05-13 | Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.
Somatostatin is a potent endocrine regulator and neurotransmitter, exerting predominantly inhibitory effects in different tissues of the body, via G-protein coupled receptors. Five such specific receptors have been identified, with different effects and tissue distribution. The multifaceted actions and effects of somatostatin make it useful as a potential therapeutical means in various pathologies; however, in clinical practice, somatostatin analogues, namely octreotide, lanreotide and pasireotide, are commonly used instead, due to their increased half-life and increased receptor selectivity, with pasireotide showing a more extensive receptor binding profile and high affinity for somatotastin receptor (SSTR) 5, which may prove effective in cases of resistance to first-generation analogues. Apart from their many uses in neoplastic pathologies, somatostatin analogues represent viable treatment choices in some ocular pathologies, congenital hyperinsulinism, gastrointestinal bleedings and portal hypertension, acute pancreatitis, and dumping syndrome. They have also been used in some cases, with varying degrees of success, in patients with post-surgical gastrointestinal and lymphatic fistulas, refractory chronic diarrhoea and polycystic kidney disease; many applications in paediatric patients have also been documented. The aim of this review is to present the applications of somatostatin and its analogues as alternative or second-line therapies, along with insights into their effectiveness and future potential.
2025-11-07 | Advances in Pharmacotherapy for Congenital Hyperinsulinism.
Congenital hyperinsulinism (CHI) is a rare disorder causing persistent hypoglycaemia in infants due to excessive insulin secretion from pancreatic β-cells. It has genetic causes, primarily mutations in ATP-sensitive potassium channel genes (ABCC8, KCNJ11). CHI manifests in three forms-focal, diffuse, and atypical-distinguished by histology and genetics, influencing treatment strategies. Early diagnosis and tailored management are vital to prevent neurological damage. While transient CHI resolves spontaneously, permanent CHI often requires complex medical and/or surgical intervention. Despite advances, long-term neurodisability remains high, highlighting increased need to improve monitoring as well as better therapies with lesser side effects. Acute treatment aims to rapidly normalize glucose levels and long-term treatments include diazoxide (KATP channel agonist) to suppress insulin secretion, though its effectiveness depends on genetic mutation type. Other therapies include somatostatin analogues. Newer emerging therapies include novel glucagon analogues, monoclonal antibodies targeting insulin receptors, GLP-1 receptor antagonist, and selective somatostatin receptor agonist, currently under clinical trials. Along with medical treatment, children may require additional feeding support with carbohydrate supplementation using glucose polymers and special formulas. Continuous glucose monitoring aids detection but has limitations. Surgery is preferred for focal lesions to potentially cure CHI.
2025-10-13 | Treatment of Congenital Hyperinsulinism With a Novel, Long-acting Glucagon Analogue.
Congenital hyperinsulinism (HI) is a disorder of insulin regulation that results in hypoketotic hypoglycemia and is associated with a high risk of neurological sequalae from hypoglycemia-induced brain damage. There is only 1 Food and Drug Administration-approved drug for the treatment of HI, and up to 60% of patients do not respond to it; thus, there is a significant unmet need for new treatments. We report a case of a 29-year-old female with HI due to an activating glucokinase pathogenic variant, who was diagnosed as an adult and continued to have persistent hypoglycemia despite standard-of-care therapy. The patient was enrolled in the phase II clinical trial evaluating efpegerglucagon, a novel long-acting glucagon analog. She has continued treatment with efpegerglucagon through a single-patient Investigational New Drug Expanded Access Program and has demonstrated improved glycemic control throughout 10 months of treatment. Efpegerglucagon may be a viable treatment option or adjunct therapy for patients with HI who are unresponsive or partially responsive to currently available therapies.
small molecules
2026-09-24 | A Novel ABCC8 Variant in an Adult with Hyperinsulinemic Hypoglycemia Suggestive of Congenital Hyperinsulinism: A Case Report.
Background and Clinical Significance: Congenital hyperinsulinism (CHI) is a disorder involving excessive insulin secretion due to mutations in the insulin regulation pathways. Patients are typically diagnosed during infancy following recurrent hypoglycemic events, which may lead to irreversible neurologic damage if left untreated. Adult presentation and diagnosis are rare. Case Presentation: Here, we report the unusual case of a 41-year-old patient who presented with recurrent episodes of hyperinsulinemic hypoglycemia. An extensive diagnostic evaluation yielded no evidence of an acquired cause. Genetic testing revealed a heterozygous novel c.4078G>C substitution in the ABCC8 gene, which plays a role in the insulin secretion pathway. This variant may have been the cause for CHI going unrecognized during the patient's childhood and could have also contributed to his uncontrolled convulsive disorder. Treatment with diazoxide and octreotide led to significant clinical improvement, with no severe hypoglycemic events during the final week of hospitalization. Conclusions: This case emphasizes the importance of considering congenital hyperinsulinism in the differential diagnosis of adult patients evaluated for hyperinsulinemic hypoglycemia, especially when standard workup fails to identify an underlying cause.
2026-09-13 | Demand Breastfeeding in Infants using Diazoxide to manage Congenital Hyperinsulinism.
Congenital Hyperinsulinism (CHI) is a rare condition which causes severe and profound hypoglycaemia. Breastfeeding is often stopped at diagnosis of CHI to reduce the likelihood of fluid overload during treatment with diazoxide, but without supportive evidence. Breastfeeding confers numerous advantages to all newborn babies and their mothers and may be safe and effective in babies with CHI. We aimed to evaluate whether demand breastfeeding in babies and infants with CHI receiving diazoxide therapy maintains safe glycaemic stability without risk of fluid overload. A retrospective observational review was undertaken to test safety, efficacy and acceptability of breastfeeding alongside diazoxide treatment in 17 infants with biochemically confirmed CHI. Data was collected on feeding method, glycaemic outcomes, adverse effects, signs/symptoms of fluid overload and genetic aetiology of CHI. The cohort included 17 infants (13 males, 4 females). Two patients had genetic forms of CHI; due to ABCC8 and HNF4A variants, while the remaining infants were diagnosed with transient CHI. All infants were demand breastfed; four infants transitioned from restricted bottle feeding to successful demand breastfeeding during the treatment course. Duration of diazoxide therapy ranged from 5-13 weeks in patients with transient CHI. The two patients with genetic CHI required prolonged therapy, with treatment durations of 9-18 months at the time of the study. Glycaemic stability was maintained throughout the treatment period without any increase in hypoglycaemic episodes during transfer to breastfeeding or reductions in diazoxide. There was no clinical evidence of fluid overload across the patient cohort. No diazoxide related adverse effects were observed, and therapy did not interfere with breastfeeding progression. Study findings support the feasibility and safety of demand breastfeeding in infants receiving diazoxide for CHI. This supports metabolic stability and parental feeding goals. These findings suggest that breastfeeding should not be routinely discouraged in this population and can be safely pursued with appropriate monitoring.
2026-08-19 | Glucagon in Endocrine and Metabolic Practice: A Critical Narrative Review of Stimulation Testing, Diagnostic Cut-points and Therapeutic Use in Children, Adolescents and Adults
Glucagon occupies an unusual position in clinical endocrinology. The same 29-amino-acid peptide serves as a provocative agent for pituitary function testing, as an emergency treatment for severe hypoglycaemia, as a continuous infusion in hyperinsulinaemic states of infancy, and, through receptor co-agonism, as a component of the newest generation of cardiometabolic drugs. These applications have developed in parallel, largely within separate literatures, and the assumptions that underpin them have rarely been examined together. This review evaluates the evidence accumulated over approximately a quarter of a century on the glucagon stimulation test and on therapeutic glucagon across the paediatric and adult lifespan, with particular attention to the derivation, transportability and validity of diagnostic cut-points. Evidence was identified through structured searching of biomedical and bibliographic sources and appraised for design adequacy, reference-standard quality, sample size, assay dependence and generalisability. Three findings dominate the synthesis. First, the growth hormone cut-point for the glucagon stimulation test is not a fixed biological threshold but a function of dose regimen, adiposity, glucose tolerance, age and assay calibration; the widely used threshold of 3 µg/L overdiagnoses deficiency in overweight adults, and the proposed alternative of 1 µg/L rests on small validation cohorts. Second, the corticotroph read-out from the same test performs considerably less well than the somatotroph read-out, and several independent series show a broad indeterminate zone in which the test cannot classify patients reliably. Third, therapeutic glucagon has been transformed by stable ready-to-use formulations and by the analogue dasiglucagon, with randomised evidence in severe hypoglycaemia, congenital hyperinsulinism and post-bariatric hypoglycaemia, although comparative effectiveness data and long-term paediatric safety data remain sparse. Priorities include multicentre cut-point validation stratified by body mass index and assay platform, harmonised cortisol thresholds, and adequately powered comparisons between glucagon formulations in real-world hypoglycaemia.
2026-08-06 | Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.
KATP-channel-related hyperinsulinism (KATPHI) is a rare genetic disorder of the pancreatic beta cells, manifesting as life-threatening hypoglycemia in neonates due to excessive insulin secretion. Management of the severe diffuse form of KATPHI currently lacks treatment options, as the first-line therapy octreotide is often insufficiently effective, necessitating radical pancreatectomy in many patients. In this study, we differentiated stem cells carrying the KATPHI-causing mutation KCNJ11-/- to stem cell-derived islets (SC-islets) to develop new pharmaceutical therapies for KATPHI. We tested seven candidate molecules in vitro and the most effective ones in vivo in immunocompromised mice that were transplanted with the human KCNJ11-/- SC-islets. KCNJ11 -/- SC-islets inappropriately secreted 3.9 times more insulin in low glucose than KCNJ11+/+ controls. Transplanted KCNJ11-/- SC-islets caused persistent hyperinsulinemia and hypoglycemia to the recipient mice. We tested acyl-ghrelin identified in our in vitro experiments and its long-acting analogue relamorelin in these mice. Acyl-ghrelin and relamorelin alone increased fasting blood glucose. Combining relamorelin with octreotide increased blood glucose synergistically, ie, more than the sum of each drug alone, reverting hypoglycemia to normoglycemia while reducing the excessive insulin secretion. We show that ghrelin-receptor agonists have acute anti-hypoglycemic effects in a humanized mouse model of KATPHI, especially when combined with octreotide. Relamorelin has been tested in >650 diabetic adults with little side effects, leading us to propose relamorelin-octreotide combination for further development as a therapeutic candidate for severe KATPHI patients.
2026-07-23 | Indocyanine green fluorescence cholangiography enables safe laparoscopic near-total pancreatectomy for diffuse congenital hyperinsulinism.
Laparoscopic near-total pancreatectomy (NTP) for diffuse congenital hyperinsulinism (CHI) may reduce morbidity compared with open surgery. However, it is technically limited by uncertainty regarding the intrapancreatic common bile duct (CBD) course, risking bile duct injury or inadequate resection. We evaluated whether near-infrared indocyanine green fluorescence cholangiography (NIR ICG FC) improves intraoperative identification of the intrapancreatic CBD and supports laparoscopic NTP for medically-refractory diffuse CHI. We performed a retrospective single-centre review of consecutive infants undergoing laparoscopic NTP with NIR ICG FC for diffuse CHI (2021-2025). Intravenous ICG (0.5 mg/kg) was administered 10-15 h preoperatively. Outcomes included feasibility of CBD visualisation, extent of resection, biliary complications, postoperative recovery, persistence of hyperinsulinism and medium-term endocrine/exocrine function. Five infants underwent laparoscopic NTP at a median age of 3 months (range 2-6). The intrapancreatic CBD was visualised in all cases, enabling a consistent 95% resection without conversion to open surgery. There were no bile duct injuries. Enteral feeding commenced at a median of 3 postoperative days (range 2-4). One patient developed transient obstructive jaundice on postoperative day 13 that resolved with conservative management. At a median follow-up of 30 months (range 20-51), three infants had residual hyperinsulinism (managed by feeding strategies in two and medication in one), and one had exocrine insufficiency requiring enzyme supplementation; no child had diabetes at latest follow up. NIR ICG fluorescence cholangiography provides real time delineation of the intrapancreatic CBD and can support a safe minimally invasive approach to near-total pancreatectomy for diffuse CHI.
gene therapies
2025-05-18 | Comprehensive clinical and molecular characterization with long-term outcomes in 40 patients with congenital hyperinsulinism.
Congenital hyperinsulinism (CHI) represents the most frequent cause of recurrent hypoglycemia in neonates and infants, stemming from defects in the regulatory pathways of insulin secretion from pancreatic beta cells. This study aims to assess the clinical and genetic characteristics of a CHI cohort and to discuss the complexities involved in managing this heterogeneous disorder. Forty patients (23 girls) with CHI were included in the study. Data on the diagnosis and treatment of CHI were obtained from the medical records. The median age at diagnosis was 1.4 months (range 0.1-30 months). The mean gestational age was 37.8 ± 2.4 weeks, and the birth weight was 1.1 ± 2.0 SDS. The consanguinity ratio was 35.0%. Median glucose, insulin, and C-peptide concentrations at diagnosis were 34.0 mg/dl (IQR 25.2-41.7), 12.4µU/ml (IQR 4.4-27.1), and 1.5 ng/ml (IQR 0.7-3.8), respectively. Molecular genetic diagnosis could be established in 62.5% (n = 25). Pathogenic variants were predominantly identified in the KATP channel genes (17/25, 68%), with the ABCC8 being the most frequent (n = 15; biallelic: 8, monoallelic: 7). KCNJ11 variants were identified in two (5.0%), GLUD1 variants in three (7.5%), and HADH variants in five patients (12.5%). Pancreatectomy was performed in 10 patients, with a mean age at the time of surgery of 3.9 ± 3.2 months. The genetic etiology was identified in all patients who underwent pancreatectomy, all of whom had defects in the KATP channel. ABCC8 variants were detected in nine (biallelic: 5, monoallelic: 4), while a biallelic variant in the KCNJ11 was identified in one case. A molecular genetic diagnosis was identified in approximately two-thirds of our cohort, underscoring the significance of genetic testing in the management of CHI. Ongoing advances in genetic technologies are anticipated to enhance our understanding of the etiopathogenesis of CHI and support the development of more personalized therapeutic strategies. Although the genotype-phenotype correlation remains only partially elucidated, specific genetic variants may provide predictive insights into treatment resistance, thereby informing more targeted treatment approaches.
2025-04-11 | The genetics of low and high birthweight and their relationship with cardiometabolic disease.
Low birthweight infants are at increased risk not only of mortality, but also of type 2 diabetes mellitus and CVD in later life. At the opposite end of the spectrum, high birthweight infants have increased risk of birth complications, such as shoulder dystocia, neonatal hypoglycaemia and obesity, and similarly increased risk of type 2 diabetes mellitus and CVD. However, previous genome-wide association studies (GWAS) of birthweight in the UK Biobank have primarily focused on individuals within the 'normal' range and have excluded individuals with high and low birthweight (<2.5 kg or >4.5 kg). The aim of this study was to investigate genetic variation associated within the tail ends of the birthweight distribution, to: (1) see whether the genetic factors operating in these regions were different from those that explained variation in birthweight within the normal range; (2) explore the genetic correlation between extremes of birthweight and cardiometabolic disease; and (3) investigate whether analysing the full distribution of birthweight values, including the extremes, improved the ability to detect genuine loci in GWAS. We performed case-control GWAS analysis of low (<2.5 kg) and high (>4.5 kg) birthweight in the UK Biobank using REGENIE software (Nlow=20,947; Nhigh=12,715; Ncontrols=207,506) and conducted three continuous GWAS of birthweight, one including the full range of birthweights, one involving a truncated GWAS including only individuals with birthweights between 2.5 and 4.5 kg and a third GWAS that winsorised birthweight values <2.5 kg and >4.5 kg. Additionally, we performed bivariate linkage disequilibrium (LD) score regression to estimate the genetic correlation between low/normal/high birthweight and cardiometabolic traits. Bivariate LD score regression analyses suggested that high birthweight had a mostly similar genetic aetiology to birthweight within the normal range (genetic correlation coefficient [rG]=0.91, 95% CI 0.83, 0.99), whereas there was more evidence for a separate set of genes underlying low birthweight (rG=-0.74, 95% CI 0.66, 0.82). Low birthweight was also significantly positively genetically correlated with most cardiometabolic traits and diseases we examined, whereas high birthweight was mostly positively genetically correlated with adiposity and anthropometric-related traits. The winsorisation strategy performed best in terms of locus detection, with the number of independent genome-wide significant associations (p<5×10-8) increasing from 120 genetic variants at 94 loci in the truncated GWAS to 270 genetic variants at 178 loci, including 27 variants at 25 loci that had not been identified in previous birthweight GWAS. This included a novel low-frequency missense variant in the ABCC8 gene, a gene known to be involved in congenital hyperinsulinism, neonatal diabetes mellitus and MODY, that was estimated to be responsible for a 170 g increase in birthweight amongst carriers. Our results underscore the importance of genetic factors in the genesis of the phenotypic correlation between birthweight and cardiometabolic traits and diseases.
2024-12-25 | Case report: Duplication of the GCK gene is a novel cause of nesidioblastosis: evidence from a case with Silver-Russell syndrome-like phenotype related to chromosome 7.
Silver-Russell syndrome (SRS) is a syndrome characterized by prenatal and postnatal growth retardation, facial features, and body asymmetry. SRS is often complicated with hypoglycemia, whose etiology is unclear. We describe the clinical course of 25-year-old man with hypoglycemia. We diagnosed him with hyperinsulinemic hypoglycemia (HH) and treated him with laparoscopic distal pancreatectomy. Histological examination led to a diagnosis of nesidioblastosis. The juvenile onset of his nesidioblastosis and its slowly progressive course suggested a genetic etiology. Whole-exome sequencing (WES) identified the heterozygous NR0B2 Ala195Ser variant, which alone was unlikely to cause nesidioblastosis because this variant is sometimes detected in the Japanese population. Copy number analysis using WES data suggested duplication in chromosome 7, and subsequent G-banding chromosome analysis confirmed mos dup(7)(p11.2p14). We determined that the patient had SRS-like phenotype based on his clinical features and this duplication. Furthermore, we found that the duplicated region contained the GCK gene, whose gain-of function variants could cause HH. Taken together, the patient's HH may have been caused by duplication of the GCK gene, which could be a novel cause of nesidioblastosis.
2023-07-20 | A novel mutation in the KCNJ11 gene (p.Val36Glu), predisposes to congenital hyperinsulinemia.
The hypoglycemia induced by insulin hypersecretion in congenital hyperinsulinemia (CHI), a rare life-threatening condition can lead to irreversible brain damage in neonates. Inactivating mutations in the genes encoding KATP channel (ABCC8 and KCNJ11) as well as HNF4A, HNF1A, HADH, UCP2, and activating mutations in GLUD1, GCK, and SLC16A1 have been identified as causal. A 3-month-old male infant presenting tonic-clonic seizures and hyperinsulinemia was clinically assessed and subjected to genetic analysis. Besides the index patient, his parents were clinically investigated, and a detailed family history was also recorded. The laboratory investigations and the genetic test results of the parents were compared with the index patient. The biochemical and hormonal profile of the patient confirmed his suffering from CHI and did not respond to diazoxide treatment. The genetic testing revealed that the subject harbored a novel homozygous missense mutation in the KCNJ11 gene, (c.107T>A, p.Val36Glu.). The bioinformatic analysis revealed that valine is highly conserved and predicted that the variant allele (p.Val36Glu) is likely pathogenic and causal for CHI. Parents were heterozygous carriers and did not report any abnormal metabolic profile. Identification of such mutations is critical and likely to change the therapeutic interventions for such patients in the future.
2022-11-08 | Integration of genomic analysis and transcript expression of ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism.
The focal form of CHI is caused by an autosomal recessive pathogenic variant affecting the paternal homologue of genes ABCC8 or KCNJ11 and a second somatic event specifically occurring in the affected islet of Langerhans. The approach of this study was to integrate the genetic changes occurring in pancreatic focal lesions of CHI at the genomic and transcriptional level. Patients receiving therapeutic surgery and with proven ABCC8 or KCNJ11 pathogenic variants were selected and analyzed for loss of heterozygosity (LOH), changes in copy number and uniparental disomy (UPD) on the short am of chromosome 11 by molecular microarray analysis and methylation-specific MLPA. Gene expression was analyzed by RT-PCR and Massive Analysis of cDNA Ends (MACE). Both genes, ABCC8 and KCNJ11, are located in proximity to the Beckwith-Wiedemann (BWS) imprinting control region on chromosome 11p15. Somatic paternal uniparental isodisomy (UPD) at chromosome 11p was identified as second genetic event in focal lesions resulting in LOH and monoallelic expression of the mutated ABCC8/KCNJ11 alleles. Of five patients with samples available for microarray analysis, the breakpoints of UPD on chromosome 11p were different. Samples of two patients were analyzed further for changes in gene expression. Profound downregulation of growth suppressing genes CDKN1 and H19 was detected in focal lesions whereas growth promoting gene ASCL2 and pancreatic transcription factors of the endocrine cell lineage were upregulated. Paternal UPD on the short arm of chromosome 11 appears to be the major second genetic event specifically within focal lesions of CHI but no common breakpoint for UDP can be delineated. We show for the first time upregulation of growth promoting ASCL2 (achaete-scute homolog 2) suggestive of a driving factor in postnatal focal expansion in addition to downregulation of growth suppressing genes CDKN1C and H19.
cell therapies
2026-09-28 | Congenital Hyperinsulinism With Paternally Inherited ABCC8 Variants: A Single Center Experience Over a Decade in Singapore.
ABCC8 pathogenic variants have been found to cause neonatal diabetes mellitus (NDM), maturity-onset diabetes of the young (MODY) and congenital hyperinsulinism (CHI), depending on the nature of the mutation. Few studies have reported on the carrier frequency of CHI-related ABCC8 variants. In Singapore, the carrier rate is 1 in 754. Paternally inherited ABCC8 recessive variants have been classically associated with focal lesions causing CHI. In our case series of five patients with paternally inherited ABCC8 variants, one patient had a second maternally inherited recessive variant, making him a compound heterozygous genotype presenting with severe, neonatal onset, diffuse disease that was not responsive to diazoxide. The remaining four patients had a single paternally inherited ABCC8 variant, of which three were previously reported to be recessive variants-only 1 had a focal lesion while the rest had diffuse disease. A comprehensive review of our cases suggests that patients with paternally inherited ABCC8 variants, whether autosomal recessive, heterozygous, or associated with genetic syndromes, were heterogeneous in their clinical manifestations and cannot be reliably distinguished based on their initial clinical presentation. A deeper understanding of the genotype-phenotype correlation of ABCC8-related CHI will require further research and functional analyses. Both a genetic diagnosis and imaging using 18F-DOPA-PET should be pursued in a timely manner once diazoxide unresponsiveness has been established. Single-stage near-total pancreatectomy may be considered for patients with diffuse disease.
2026-09-27 | Laparoscopic Pancreatectomy for Persistent Hyperinsulinemic Hypoglycemia of Infancy - Case Series.
Hypoglycemia in neonates can be attributed to Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI). Even though initial management involves the use of medical agents, requirement of surgery is seen in a large number of cases, particularly in those who are nonresponsive. Open pancreatectomy has been the gold standard in the management of PHHI, but there has been a recent inclination toward the use of minimally invasive procedures, namely laparoscopic pancreatectomy to achieve similar results with lesser morbidity. The aim of this study is to describe the presentation, key technical points, and outcomes of laparoscopic pancreatectomy in the management of PHHI. A retrospective study which was conducted between January 2019 and September 2024 which included 7 children who were diagnosed to have PHHI. All seven patients who were operated were infants with an average age of 4 months (range 1-5 months), with the youngest patient being one and half months of age. All of them underwent a laparoscopic pancreatectomy with the average duration of the procedure being 60 min and with very minimal blood loss. A distal pancreatectomy was performed in one infant while a near total pancreatectomy was performed in the other six infants. Euglycemia was achieved in six cases and they are on regular follow-up, with the longest duration of follow-up being 4 years and 3 months. The average duration of follow-up has been 3 years and 6 months, ranging from 1 month to 4 years and 3 months. One child had postoperative requirement of octreotide for 2 weeks after which it was tapered and stopped. One child had persistent hypoglycemic episodes and required a completion pancreatectomy 6 months after the initial surgery. No intraoperative or postoperative complications were noted. Laparoscopic pancreatectomy is an excellent tool in the armamentarium of surgeons looking for an effective surgical modality to treat PHHI with minimal morbidity.
2026-09-13 | Minimally Invasive Surgical Treatment of Different Types of Hyperinsulinism.
Congenital hyperinsulinism of infancy (CHI) is a rare and genetically heterogeneous disorder that often requires surgical intervention when medical therapy fails. Distinct pathological subtypes of CHI necessitate different surgical strategies. Minimally invasive surgery has increasingly been considered a safe and feasible approach for these patients. This study aimed to evaluate the outcomes of minimally invasive surgery for different CHI subtypes at our center. We conducted a retrospective single-center review of 110 patients with CHI who underwent minimally invasive surgery between 2011 and 2024. Pathological subtypes comprised 45 focal, 64 diffuse, and one atypical case. 18F-DOPA PET/CT was performed in 97 patients, demonstrating a diagnostic concordance rate of 94.8%. Conversion to open surgery was required in three patients (two focal and one diffuse) because of intraoperative bleeding, whereas the remaining 107 procedures were completed minimally invasively, including eight robotic-assisted operations (five focal and three diffuse). Among patients with focal CHI, 91.1% achieved cure without postoperative medication. In diffuse disease, near-total pancreatectomy resulted in a higher cure rate than subtotal resection (66.7% vs. 51.2%) but was associated with an increased incidence of postoperative hyperglycemia and common bile duct injury. Two patients required reoperation because of persistent hypoglycemia. Minimally invasive surgery is a safe and feasible treatment for CHI, providing outcomes comparable to open surgery. Focal CHI is associated with excellent postoperative outcomes and may benefit from earlier surgical intervention. For diffuse CHI, approximately 95% pancreatectomy may achieve satisfactory glycemic control while balancing the risk of postoperative complications.
2026-01-31 | Robotic versus Open Pancreatectomy for Focal Congenital Hyperinsulinism in Infants: A Single-Center Study.
Focal forms of congenital hyperinsulinism (FoCHI) are rare pediatric conditions managed using established metabolic and surgical protocols. To date, the use of a robotic approach for this surgery in children has not been described. We present our initial experience with robotic pancreatectomy, compared with the open approach, for the management of FoCHI. We conducted a retrospective, single-center study involving 25 children who underwent pancreatectomy for CHI between 2011 and 2024. Collected data included patient demographics, surgical details, complications, and post-operative outcomes. The Da Vinci Xi robotic system was used for all robotic procedures. Ten patients underwent robotic pancreatectomy, and 10 underwent open surgery; five children treated laparoscopically were excluded. There were no significant differences between the robotic and open groups in median weight at surgery (7.7 kg vs. 7.3 kg, p = 0.7), median age (7 months vs. 5.9 months, p = 0.48), median operative time (298 minutes vs. 285 minutes, p = 0.5), length of stay (14 days vs. 14.5 days, p = 0.26), or time to postoperative feeding resumption (4 days vs. 4.5 days, p = 0.68). Intraoperatively, 80% of lesions were visible on the pancreatic surface. Two cases of incomplete resection occurred in each group; after multidisciplinary review, both patients in the robotic group required a second procedure. No intraoperative bleeding or conversions were reported. The overall cure rate was 90% in the robotic group and 80% in the open surgery group. This preliminary study suggests that robotic pancreatectomy for congenital hyperinsulinism may be both safe and feasible. The robotic approach provides enhanced visualization of small vessels, enabling limited dissection and safe resection. Given the sample size, further studies are required to confirm these findings.
2025-09-23 | A rare case of congenital hyperinsulinism in a child — when morphology determines treatment tactics
Background. A clinical case of an encapsulated focal form of congenital hyperinsulinism in a young child is presented. A comprehensive examination was performed, including molecular genetic analysis, radionuclide diagnostics (PET-CT with 18F-DOPA) and intraoperative histological examination. During morphological analysis, an encapsulated focus of β-cell adenomatous hyperplasia was verified, located in the head of the pancreas. This finding necessitated an extended organ resection. It is particularly noteworthy that there is a clear fibrous capsule around the pathological focus, which presents a diagnostic challenge in differentiating this pathology from an insulinoma. The postoperative period was uneventful, and stable normoglycemia was achieved, which ultimately confirmed the positive outcome of the treatment and the patient's recovery. The unique feature of this clinical case is that it represents the first recorded example of the focal form of congenital hyperinsulinism, characterized by a well-defined fibrous capsule combined with adenomatosis lacking visible boundaries. As of today, similar observations have not been found in available publications from domestic medical centers, which highlights the rarity of the described case and its significance for expanding knowledge about the spectrum of focal forms of this disease. Analysis of this morphological variant highlights the importance of performing a rapid histological examination of tissues during surgery, which in this clinical case was a key factor in determining the extent of the resection. This decision allowed us not to be limited to just the encapsulated formation and ultimately led to the patient's full recovery. Conclusion. This case demonstrates the importance of a multidisciplinary approach in the diagnosis of rare forms of congenital hyperinsulinism and highlights the need for a thorough histopathological examination of the surgical material to achieve correct clinical decision.
other
2023-06-26 | Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
Congenital hyperinsulinism (HI) is a genetic disorder in which pancreatic β-cell insulin secretion is excessive and results in hypoglycemia that, without treatment, can cause brain damage or death. Most patients with loss-of-function mutations in ABCC8 and KCNJ11, the genes encoding the β-cell ATP-sensitive potassium channel (KATP), are unresponsive to diazoxide, the only U.S. Food and Drug Administration–approved medical therapy and require pancreatectomy. The glucagon-like peptide 1 receptor (GLP-1R) antagonist exendin-(9-39) is an effective therapeutic agent that inhibits insulin secretion in both HI and acquired hyperinsulinism. Previously, we identified a highly potent antagonist antibody, TB-001-003, which was derived from our synthetic antibody libraries that were designed to target G protein–coupled receptors. Here, we designed a combinatorial variant antibody library to optimize the activity of TB-001-003 against GLP-1R and performed phage display on cells overexpressing GLP-1R. One antagonist, TB-222-023, is more potent than exendin-(9-39), also known as avexitide. TB-222-023 effectively decreased insulin secretion in primary isolated pancreatic islets from a mouse model of hyperinsulinism, Sur1−/− mice, and in islets from an infant with HI, and increased plasma glucose levels and decreased the insulin to glucose ratio in Sur1−/− mice. These findings demonstrate that targeting GLP-1R with an antibody antagonist is an effective and innovative strategy for treatment of hyperinsulinism. Article Highlights Patients with the most common and severe form of diazoxide-unresponsive congenital hyperinsulinism (HI) require a pancreatectomy. Other second-line therapies are limited in their use because of severe side effects and short half-lives. Therefore, there is a critical need for better therapies. Studies with the glucagon-like peptide 1 receptor (GLP-1R) antagonist, avexitide (exendin-(9-39)), have demonstrated that GLP-1R antagonism is effective at lowering insulin secretion and increasing plasma glucose levels. We have optimized a GLP-1R antagonist antibody with more potent blocking of GLP-1R than avexitide. This antibody therapy is a potential novel and effective treatment for HI.
2022-11-01 | Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism
Gene expression is tightly regulated, with many genes exhibiting cell-specific silencing when their protein product would disrupt normal cellular function1. This silencing is largely controlled by non-coding elements, and their disruption might cause human disease2. We performed gene-agnostic screening of the non-coding regions to discover new molecular causes of congenital hyperinsulinism. This identified 14 non-coding de novo variants affecting a 42-bp conserved region encompassed by a regulatory element in intron 2 of the hexokinase 1 gene (HK1). HK1 is widely expressed across all tissues except in the liver and pancreatic beta cells and is thus termed a ‘disallowed gene’ in these specific tissues. We demonstrated that the variants result in a loss of repression of HK1 in pancreatic beta cells, thereby causing insulin secretion and congenital hyperinsulinism. Using epigenomic data accessed from public repositories, we demonstrated that these variants reside within a regulatory region that we determine to be critical for cell-specific silencing. Importantly, this has revealed a disease mechanism for non-coding variants that cause inappropriate expression of a disallowed gene. De novo variants altering a conserved region in an intron of HK1 cause congenital hyperinsulinism by perturbing the activity of a putative cell type-specific regulatory element.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
19 orphan drug designations for Congenital isolated hyperinsulinism.
19 orphan drug designations for Congenital isolated hyperinsulinism.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
solution stable glucagon analog | peptides | FDA | — | AmideBio, Inc. |
Pegylated Glucagon Receptor Agonist | peptides | FDA | — | Pegbio Co. Ltd. |
Zavolosotine | small molecules | EMA | — | Crinetics Pharmaceuticals Europe GmbH |
solution stable glucagon analog | peptides | FDA | — | AmideBio |
Exendin (9-39) | peptides | EMA | Amylyx Pharmaceuticals EMEA B.V. | |
Glucagon analogue linked to a human immunoglobulin Fc fragment | proteins | EMA | JVM Europe B.V. | |
glucagon analog conjugated with human immunoglobulin G4 fragment | proteins | FDA | Hanmi Pharmaceutical Company, Ltd. | |
glucagon (ready-to-use) | peptides | FDA | Xeris Pharmaceuticals, Inc. | |
dihydroxyphenylalanine F 18/Fluorodopa (F18) | small molecules | FDA | Society of Nuclear Medicine and Molecular Imaging | |
dasiglucagon | peptides | FDA | Zealand Pharma A/S | |
Synthetic glucagon analogue modified to contain 7 amino acid substitutions | peptides | EMA | Zealand Pharma A/S | |
avexitide | peptides | FDA | Amylyx Pharmaceuticals, Inc. | |
Recombinant human monoclonal antibody to insulin receptor | antibodies | EMA | Rezolute (Bio) Ireland Limited | |
fully human IgG2 monoclonal antibody that binds insulin receptors | antibodies | FDA | Rezolute, Inc. | |
Glucagon | peptides | EMA | — | S-cubed Pharmaceutical Services ApS |
glucagon infusion | peptides | FDA | Xeris Pharmaceuticals, Inc. | |
glucagon | peptides | FDA | — | Biodel, Inc. |
Glucagon | peptides | EMA | — | Biodel UK Limited |
exendin-(9-39) | peptides | FDA | The Children's Hospital of Philadelphia |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.